Products for Research Use Only
RegisterLogin

Avosentan

CAT: 0804-HY-15195-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15195-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure[1][2][3][4].
CAS Number
290815-26-8
Product Name Alternative
Ro 67-0565; SPP-301
UNSPSC
12352005
Hazard Statement
H315, H319, H335, H413
Target
Endothelin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Endocrinology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/avosentan.html
Concentration
10mM
Purity
98.15
Solubility
DMSO : 6.67 mg/mL (ultrasonic)
Smiles
COC1=C(OC(C(NS(C2=NC=C(C=C2)C)(=O)=O)=NC(C3=CC=NC=C3)=N4)=C4OC)C=CC=C1
Molecular Formula
C23H21N5O5S
Molecular Weight
479.51
Precautions
H315, H319, H335, H413
References & Citations
[1]Baltatu OC, Iliescu R, Zaugg CE, Reckelhoff JF, Louie P, Schumacher C, Campos LA. Antidiuretic effects of the endothelin receptor antagonist avosentan. Front Physiol. 2012;3:103.|[2]Konieczka K, Meyer P, Schoetzau A, Neutzner A, Mozaffarieh M, Flammer J. Effect of avosentan (SPP-301) in porcine ciliary arteries. Curr Eye Res. 2011 Feb;36 (2) :118-24.|[3]Effect of SPP 301, an Endothelin Antagonist, on Intraocular Pressure in Glaucomatous Monkey Eyes By Wang, Rong-Fang; Podos, Steven M.; Serle, Janet B.; Baltatu, Ovidiu C. From Current Eye Research (2011), 36 (1), 41-46.|[4]Baltatu OC, et al. Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention. Pharmacol Res. 2014 Feb;80:9-13.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
ETA

Alternative Products

CatalogName
QLA81526-01Avosentan
A11301-50Avosentan 50mg
MBS386692-01Avosentan (SPP301)
A11301-25Avosentan 25mg
A11301-10Avosentan 10mg
A11301-5Avosentan 5mg
TRC-A794712-25MGAvosentan-d3
A11301-100Avosentan (SPP301) 100mg
A11301-1Avosentan (SPP301) 1mg
A11301-10mM-DAvosentan (SPP301) 10mM * 1mL in DMSO

Popular Products